Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
aap Implantate AG (OJ:AAQ) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment and active in medical biomaterials, fracture healing and joint replacement, boosted - according to preliminary figures - sales revenues by 36% to EUR 8,0 million (previous year: EUR 5.9 million) in the third quarter of the fiscal year 2008. Sales growth in the first nine months was 30% to EUR 24.2 million (previous year: EUR 18.6 million).
Sales growth was achieved by the above-average development of the trauma & orthopaedics segment of aap throughout the first nine months of 2008 (+57% to EUR 9.4 million) and the successful development of the aap bio implants group in the third quarter, where revenues exceeded the third quarter revenues of 2007 by 46%.
For 2008 aap anticipates an organic sales growth of more than 20%, with above-average impact on the company's operating result and net income. The publication of the full report on aap Implantate AG's third quarter of 2008 is scheduled for November 7, 2008.
____ aap is a medical technology company that develops, manufactures and markets biomaterials and implants for trauma and orthopaedics. Its product portfolio includes bone cements, bone graft substitutes, antibiotic carriers, and implants for fracture healing and joint replacement. In addition to its Berlin headquarters the company has locations in Dieburg and Obernburg near Frankfurt am Main, Düsseldorf as well as at Nijmegen in the Netherlands. aap Implantate AG has been listed in the Prime Standard segment at the Frankfurt stock exchange since May 16, 2003.
Please address any queries to: aap Implantate AG, Nanette Hüdepohl, Head of Corporate Communications, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9133; Fax: +49 30 7501 9290; n.huedepohl@aap.de
For further information about aap bio implants, visit www.aap-bioimplants.com
--- End of Message ---
aap Implantate AG Lorenzweg 5 Berlin Germany
WKN: 506660; ISIN: DE0005066609; Index: CDAX, Prime All Share, TECH All Share; Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;
